Powerup Acquisition CORP 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
Aspire Biopharma Holdings, Inc. (ASBP) filed its Form 10-Q for the period ending June 30, 2026, detailing operational losses, a substantial increase in cash, and the completion of a significant acquisition.
Aspire Biopharma Holdings, Inc. reported a substantial net loss and a 'going concern' warning for Q3 2025, while facing Nasdaq delisting for non-compliance with listing rules.
Aspire Biopharma Holdings, Inc. reported a significant net loss for Q3 2025, alongside progress in its sublingual aspirin clinical trials and ongoing Nasdaq delisting concerns.
Aspire Biopharma Holdings, Inc. reports a significant increase in net loss and accumulated deficit, raising substantial doubt about its ability to continue as a going concern, while also facing Nasdaq delisting threats.
Aspire Biopharma Holdings, Inc. filed an amended quarterly report to correct a $1 million liability understatement, revealing a material weakness in internal controls and significant financial challenges including a going concern doubt and Nasdaq non-compliance.
Aspire Biopharma Holdings reports its first quarterly results post-merger, highlighting a significant net loss and ongoing efforts to develop its sublingual drug delivery technology.
PowerUp Acquisition Corp. reported a net loss for the third quarter of 2024 and is actively pursuing a business combination with Aspire Biopharma after terminating a previous merger agreement.
PowerUp Acquisition Corp. has filed an amendment to its quarterly report on Form 10-Q for the period ended June 30, 2024, solely to restate certifications by its principal executive and financial officers.
PowerUp Acquisition Corp. has filed an amendment to its quarterly report to restate certifications by its principal executive and financial officers.
PowerUp Acquisition Corp. reported a net loss for the second quarter of 2024 and terminated its merger agreement with Visiox Pharmaceuticals.
PowerUp Acquisition Corp. reported a net loss for Q1 2024 as it continues to pursue a business combination with Visiox Pharmaceuticals and secured an extension to complete the deal.